University of Iowa Research Foundation

Ebay, Incorporated

David E Elliott

Joel V Weinstock

George J Weiner

Nainesh Nayudu

Mirac Nedim Ince

The invention relates to helminthic parasite preparations and their use for treatment or prevention of GVHD in a subject that has undergone a transplant. The invention also related to helminthic parasite preparations and their use for prevention of GVHD in a subject prior to a transplant.

Parasitic biological agents for treatment and prevention of graft versus host disease

The invention relates to a method of treating an excessive immune response including an aberrant/enhanced Th1 response by administering a helminthic parasite preparation in an amount sufficient to reduce the excessive immune response in an individual. This invention is generally directed to autoimmune diseases which involve an excessive immune response or an aberrant/enhanced Th1 response. More specifically, the present invention is directed to the treatment of Crohn's disease and ulcerative colitis, both known as IBD. While the present invention discloses specific information about the treatment of IBD, the disclosure is in no way limiting. Additionally, rheumatoid arthritis, type 1 diabetes mellitus, lupus erythematosis, sarcoidosis, multiple sclerosis, autoimmune thyroiditis, allergic rhinitis, colon polyps/colon cancer and asthma can be treated by the methods and compositions disclosed therein.

Use of parasitic biological agents for disease prevention and control

The invention relates to a method of treating an excessive immune response including an aberrant/enhanced Th1 response by administering a helminthic parasite preparation in an amount sufficient to reduce the excessive immune response in an individual. This invention is generally directed to autoimmune diseases which involve an excessive immune response or an aberrant/enhanced Th1 response. More specifically, the present invention is directed to the treatment of Crohn's disease and ulcerative colitis, both known as IBD. While the present invention discloses specific information about the treatment of IBD, the disclosure is in no way limiting. Additionally, rheumatoid arthritis, type 1 diabetes mellitus, lupus erythematosis, sarcoidosis and multiple sclerosis can be treated by the methods and compositions disclosed therein.

Growing community of inventors

North Liberty, IA, United States of America

David E Elliott